Expression of autophagy related gene Beclin1 in myelodysplastic syndrome patients and its significance.
10.7534/j.issn.1009-2137.2013.04.024
- Author:
Shao-Yuan WAN
1
;
Ri ZHANG
;
Yuan-Yuan WANG
;
Jian-Nong CEN
;
Jie ZHOU
;
Yi YANG
;
Feng JIANG
;
Zi-Xing CHEN
Author Information
1. Department of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou 215006, Jiangsu Province, China.
- Publication Type:Journal Article
- MeSH:
Anemia;
metabolism;
Apoptosis Regulatory Proteins;
genetics;
metabolism;
Autophagy;
Beclin-1;
Biomarkers, Tumor;
metabolism;
Bone Marrow Cells;
metabolism;
Humans;
Leukemia, Myeloid, Acute;
metabolism;
Membrane Proteins;
genetics;
metabolism;
Myelodysplastic Syndromes;
metabolism;
pathology;
Prognosis
- From:
Journal of Experimental Hematology
2013;21(4):936-939
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to explore the contribution of autophagy associated gene Beclin1 in the prognosis of myelodysplastic syndrome (MDS) by detecting the expression level of Beclin1 in bone marrow mononuclear cells (BMNC) from 40 MDS patients, 14 non-malignant anemia patients and 25 AML patients. The expression of Beclin1 mRNA was detected by real-time quantitative polymerase chain reaction (qRT-PCR). At the same time, the Western blot was used to analyze the expression of Beclin1 proteins. The results showed that the expression of Beclin1 in low risk MDS patients and non-malignant anemia patients was both significantly higher than that in acute myeloid leukemia patients (P < 0.01). And more interestingly, the Beclin1 mRNA expression in MDS group was negatively correlated with World Health Organization classification-based prognostic system (WPSS) score (r = -0.495). It is concluded that the expression of Beclin1 in the patients with MDS is higher than that in AML patients, and negatively correlated with WPSS scores. Beclin1 is a potential biomarker for predicting prognosis of the patients with MDS.
